Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Long-Term Investments (2021 - 2025)

Krystal Biotech's Long-Term Investments history spans 5 years, with the latest figure at $128.1 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 15.81% year-over-year to $128.1 million; the TTM value through Dec 2025 reached $128.1 million, down 15.81%, while the annual FY2025 figure was $128.1 million, 15.81% down from the prior year.
  • Long-Term Investments for Q4 2025 was $128.1 million at Krystal Biotech, down from $133.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $152.1 million in Q4 2024 and bottomed at $4.6 million in Q4 2022.
  • The 5-year median for Long-Term Investments is $62.0 million (2023), against an average of $66.3 million.
  • The largest annual shift saw Long-Term Investments plummeted 92.82% in 2022 before it skyrocketed 1537.67% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $64.4 million in 2021, then tumbled by 92.82% to $4.6 million in 2022, then skyrocketed by 1240.71% to $62.0 million in 2023, then surged by 145.53% to $152.1 million in 2024, then fell by 15.81% to $128.1 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Long-Term Investments are $128.1 million (Q4 2025), $133.1 million (Q3 2025), and $138.8 million (Q2 2025).